- Home
- MNTK vs NERV Comparison
MNTK vs NERV Comparison
Compare MNTK & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNTK | NERV |
|---|---|---|
| Founded | 1980 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.0M | 210.1M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MNTK | NERV |
|---|---|---|
| Price | $1.75 | $4.43 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $1.80 | ★ $10.50 |
| AVG Volume (30 Days) | 176.8K | ★ 379.3K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $176,382,000.00 | $41,175,600.00 |
| Revenue This Year | $18.55 | N/A |
| Revenue Next Year | $12.68 | N/A |
| P/E Ratio | $146.00 | ★ N/A |
| Revenue Growth | ★ 0.37 | N/A |
| 52 Week Low | $1.07 | $1.76 |
| 52 Week High | $2.57 | $12.46 |
Technical Indicators
Market Signals| Indicator | MNTK | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 59.37 | 46.68 |
| Support Level | $1.55 | $3.80 |
| Resistance Level | $1.84 | $4.59 |
| Average True Range (ATR) | 0.09 | 0.39 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 95.56 | 36.27 |
Price Performance
Historical ComparisonAbout MNTK Montauk Renewables Inc.
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.